Dextran sulphate sodium colitis in C57BL/6J mice is alleviated by Lactococcus lactis and worsened by the neutralization of Tumor necrosis Factor α

TNFα has a well-established role in inflammatory bowel disease that affects the gastrointestinal tract and is usually manifested as Crohn's disease or ulcerative colitis. We have compared Lactococcus lactis NZ9000 displaying TNFα-binding affibody with control Lactococcus lactis and with anti-TN...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International immunopharmacology 2017-02, Vol.43, p.219-226
Hauptverfasser: Berlec, Aleš, Perše, Martina, Ravnikar, Matjaž, Lunder, Mojca, Erman, Andreja, Cerar, Anton, Štrukelj, Borut
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 226
container_issue
container_start_page 219
container_title International immunopharmacology
container_volume 43
creator Berlec, Aleš
Perše, Martina
Ravnikar, Matjaž
Lunder, Mojca
Erman, Andreja
Cerar, Anton
Štrukelj, Borut
description TNFα has a well-established role in inflammatory bowel disease that affects the gastrointestinal tract and is usually manifested as Crohn's disease or ulcerative colitis. We have compared Lactococcus lactis NZ9000 displaying TNFα-binding affibody with control Lactococcus lactis and with anti-TNFα antibody infliximab for the treatment of mice with dextran sulphate sodium (DSS)-induced colitis. L. lactis NZ9000 alleviated the colitis severity one week after colitis induction with DSS, more effectively when administered in preventive fashion prior to, during and after DSS administration. TNFα-binding L. lactis was less effective than control L. lactis, particularly when TNFα-binding L. lactis was administered in preventive fashion. Similarly, an apparently detrimental effect of TNFα neutralization was observed in mice that were intraperitoneally administered anti-TNFα monoclonal antibody infliximab prior to colitis induction. The highest concentrations of tissue TNFα were observed in groups without DSS colitis that were treated either with TNFα-binding L. lactis or infliximab. To conclude, we have confirmed that L. lactis exerts a protective effect on DSS-induced colitis in mice. Contrary to expectations, but in line with some reports, the neutralization of TNFα aggravated disease symptoms in the acute phase of colitis and increased TNFα concentration in colon tissue of healthy mice. Nevertheless, we have demonstrated that oral administration of bacteria with surface displayed TNFα-binding affibody can interfere significantly with TNFα signaling and mimic the infliximab response in the given animal model of colitis. [Display omitted] •TNFα-binding and control L. lactis were compared with anti-TNFα antibody in colitis.•L. lactis alleviated the DSS colitis, particularly in preventive administration.•Detrimental effect of TNFα neutralization was observed.•TNFα neutralization without DSS induction highly increased tissue TNFα.
doi_str_mv 10.1016/j.intimp.2016.12.027
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1854801551</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S156757691630529X</els_id><sourcerecordid>1931697074</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-adada79d958afe0770f4db15e481698b2118c4d17615def78dcfb452bfd831aa3</originalsourceid><addsrcrecordid>eNp9kc1u1TAQhSMEoqXwBghZYsMmqSeJY2eDBLeUH12JTVlbjj1RfZXYF9sptK_Bk_AiPBOOUliwQF54PPrOGdunKJ4DrYBCd36orEt2PlZ1PlVQV7TmD4pTEFyUwCl7mGvW8ZLxrj8pnsR4oDT3W3hcnNSCNr2g7LT4cYHfU1COxGU6XquEJHpjl5loP9lkI7GO7Bh_uz_vPpHZaiS5p6YJb2yGDRluyV7p5LXXeolkyvUKOEO--RDRbUi6RuJwyYMme6eS9Y74kVwtsw-5r4OPWXS5-gTy6-fT4tGopojP7vez4svlu6vdh3L_-f3H3Zt9qZueplKZvHhveibUiJRzOrZmAIatgK4XQw0gdGuAd8AMjlwYPQ4tq4fRiAaUas6KV5vvMfivC8YkZxs1TpNy6JcoQbBWUGAMMvryH_Tgl-Dy7ST0TR7HKW8z1W7U-qIYcJTHYGcVbiVQuYYmD3ILTa6hSahlDi3LXtybL8OM5q_oT0oZeL0BmH_jxmKQUVt0Go0NqJM03v5_wm-pyqyp</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1931697074</pqid></control><display><type>article</type><title>Dextran sulphate sodium colitis in C57BL/6J mice is alleviated by Lactococcus lactis and worsened by the neutralization of Tumor necrosis Factor α</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Berlec, Aleš ; Perše, Martina ; Ravnikar, Matjaž ; Lunder, Mojca ; Erman, Andreja ; Cerar, Anton ; Štrukelj, Borut</creator><creatorcontrib>Berlec, Aleš ; Perše, Martina ; Ravnikar, Matjaž ; Lunder, Mojca ; Erman, Andreja ; Cerar, Anton ; Štrukelj, Borut</creatorcontrib><description>TNFα has a well-established role in inflammatory bowel disease that affects the gastrointestinal tract and is usually manifested as Crohn's disease or ulcerative colitis. We have compared Lactococcus lactis NZ9000 displaying TNFα-binding affibody with control Lactococcus lactis and with anti-TNFα antibody infliximab for the treatment of mice with dextran sulphate sodium (DSS)-induced colitis. L. lactis NZ9000 alleviated the colitis severity one week after colitis induction with DSS, more effectively when administered in preventive fashion prior to, during and after DSS administration. TNFα-binding L. lactis was less effective than control L. lactis, particularly when TNFα-binding L. lactis was administered in preventive fashion. Similarly, an apparently detrimental effect of TNFα neutralization was observed in mice that were intraperitoneally administered anti-TNFα monoclonal antibody infliximab prior to colitis induction. The highest concentrations of tissue TNFα were observed in groups without DSS colitis that were treated either with TNFα-binding L. lactis or infliximab. To conclude, we have confirmed that L. lactis exerts a protective effect on DSS-induced colitis in mice. Contrary to expectations, but in line with some reports, the neutralization of TNFα aggravated disease symptoms in the acute phase of colitis and increased TNFα concentration in colon tissue of healthy mice. Nevertheless, we have demonstrated that oral administration of bacteria with surface displayed TNFα-binding affibody can interfere significantly with TNFα signaling and mimic the infliximab response in the given animal model of colitis. [Display omitted] •TNFα-binding and control L. lactis were compared with anti-TNFα antibody in colitis.•L. lactis alleviated the DSS colitis, particularly in preventive administration.•Detrimental effect of TNFα neutralization was observed.•TNFα neutralization without DSS induction highly increased tissue TNFα.</description><identifier>ISSN: 1567-5769</identifier><identifier>EISSN: 1878-1705</identifier><identifier>DOI: 10.1016/j.intimp.2016.12.027</identifier><identifier>PMID: 28039805</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Anti-Inflammatory Agents - therapeutic use ; Antibodies, Neutralizing - chemistry ; Antibodies, Neutralizing - therapeutic use ; Bacteria ; Binding ; Colitis ; Colitis - chemically induced ; Colitis - therapy ; Colon ; Colon - drug effects ; Colon - immunology ; Crohn's disease ; Dextran ; Dextran Sulfate ; Digestive system ; DSS model ; Female ; Gastrointestinal tract ; Humans ; Inflammatory bowel disease ; Inflammatory bowel diseases ; Infliximab ; Infliximab - therapeutic use ; Intestinal Mucosa - drug effects ; Intestine ; Laboratory animals ; Lactococcus lactis ; Lactococcus lactis - chemistry ; Lactococcus lactis - immunology ; Mice ; Mice, Inbred C57BL ; Monoclonal antibodies ; Neutralization ; Oral administration ; Signal Transduction - drug effects ; Sodium ; Sulfates ; TNFα neutralization ; Tumor Necrosis Factor-alpha - immunology ; Tumor necrosis factor-TNF ; Tumor necrosis factor-α ; Ulcerative colitis</subject><ispartof>International immunopharmacology, 2017-02, Vol.43, p.219-226</ispartof><rights>2016 Elsevier B.V.</rights><rights>Copyright © 2016 Elsevier B.V. All rights reserved.</rights><rights>Copyright Elsevier BV Feb 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-adada79d958afe0770f4db15e481698b2118c4d17615def78dcfb452bfd831aa3</citedby><cites>FETCH-LOGICAL-c390t-adada79d958afe0770f4db15e481698b2118c4d17615def78dcfb452bfd831aa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.intimp.2016.12.027$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28039805$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Berlec, Aleš</creatorcontrib><creatorcontrib>Perše, Martina</creatorcontrib><creatorcontrib>Ravnikar, Matjaž</creatorcontrib><creatorcontrib>Lunder, Mojca</creatorcontrib><creatorcontrib>Erman, Andreja</creatorcontrib><creatorcontrib>Cerar, Anton</creatorcontrib><creatorcontrib>Štrukelj, Borut</creatorcontrib><title>Dextran sulphate sodium colitis in C57BL/6J mice is alleviated by Lactococcus lactis and worsened by the neutralization of Tumor necrosis Factor α</title><title>International immunopharmacology</title><addtitle>Int Immunopharmacol</addtitle><description>TNFα has a well-established role in inflammatory bowel disease that affects the gastrointestinal tract and is usually manifested as Crohn's disease or ulcerative colitis. We have compared Lactococcus lactis NZ9000 displaying TNFα-binding affibody with control Lactococcus lactis and with anti-TNFα antibody infliximab for the treatment of mice with dextran sulphate sodium (DSS)-induced colitis. L. lactis NZ9000 alleviated the colitis severity one week after colitis induction with DSS, more effectively when administered in preventive fashion prior to, during and after DSS administration. TNFα-binding L. lactis was less effective than control L. lactis, particularly when TNFα-binding L. lactis was administered in preventive fashion. Similarly, an apparently detrimental effect of TNFα neutralization was observed in mice that were intraperitoneally administered anti-TNFα monoclonal antibody infliximab prior to colitis induction. The highest concentrations of tissue TNFα were observed in groups without DSS colitis that were treated either with TNFα-binding L. lactis or infliximab. To conclude, we have confirmed that L. lactis exerts a protective effect on DSS-induced colitis in mice. Contrary to expectations, but in line with some reports, the neutralization of TNFα aggravated disease symptoms in the acute phase of colitis and increased TNFα concentration in colon tissue of healthy mice. Nevertheless, we have demonstrated that oral administration of bacteria with surface displayed TNFα-binding affibody can interfere significantly with TNFα signaling and mimic the infliximab response in the given animal model of colitis. [Display omitted] •TNFα-binding and control L. lactis were compared with anti-TNFα antibody in colitis.•L. lactis alleviated the DSS colitis, particularly in preventive administration.•Detrimental effect of TNFα neutralization was observed.•TNFα neutralization without DSS induction highly increased tissue TNFα.</description><subject>Animals</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Antibodies, Neutralizing - chemistry</subject><subject>Antibodies, Neutralizing - therapeutic use</subject><subject>Bacteria</subject><subject>Binding</subject><subject>Colitis</subject><subject>Colitis - chemically induced</subject><subject>Colitis - therapy</subject><subject>Colon</subject><subject>Colon - drug effects</subject><subject>Colon - immunology</subject><subject>Crohn's disease</subject><subject>Dextran</subject><subject>Dextran Sulfate</subject><subject>Digestive system</subject><subject>DSS model</subject><subject>Female</subject><subject>Gastrointestinal tract</subject><subject>Humans</subject><subject>Inflammatory bowel disease</subject><subject>Inflammatory bowel diseases</subject><subject>Infliximab</subject><subject>Infliximab - therapeutic use</subject><subject>Intestinal Mucosa - drug effects</subject><subject>Intestine</subject><subject>Laboratory animals</subject><subject>Lactococcus lactis</subject><subject>Lactococcus lactis - chemistry</subject><subject>Lactococcus lactis - immunology</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Monoclonal antibodies</subject><subject>Neutralization</subject><subject>Oral administration</subject><subject>Signal Transduction - drug effects</subject><subject>Sodium</subject><subject>Sulfates</subject><subject>TNFα neutralization</subject><subject>Tumor Necrosis Factor-alpha - immunology</subject><subject>Tumor necrosis factor-TNF</subject><subject>Tumor necrosis factor-α</subject><subject>Ulcerative colitis</subject><issn>1567-5769</issn><issn>1878-1705</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1u1TAQhSMEoqXwBghZYsMmqSeJY2eDBLeUH12JTVlbjj1RfZXYF9sptK_Bk_AiPBOOUliwQF54PPrOGdunKJ4DrYBCd36orEt2PlZ1PlVQV7TmD4pTEFyUwCl7mGvW8ZLxrj8pnsR4oDT3W3hcnNSCNr2g7LT4cYHfU1COxGU6XquEJHpjl5loP9lkI7GO7Bh_uz_vPpHZaiS5p6YJb2yGDRluyV7p5LXXeolkyvUKOEO--RDRbUi6RuJwyYMme6eS9Y74kVwtsw-5r4OPWXS5-gTy6-fT4tGopojP7vez4svlu6vdh3L_-f3H3Zt9qZueplKZvHhveibUiJRzOrZmAIatgK4XQw0gdGuAd8AMjlwYPQ4tq4fRiAaUas6KV5vvMfivC8YkZxs1TpNy6JcoQbBWUGAMMvryH_Tgl-Dy7ST0TR7HKW8z1W7U-qIYcJTHYGcVbiVQuYYmD3ILTa6hSahlDi3LXtybL8OM5q_oT0oZeL0BmH_jxmKQUVt0Go0NqJM03v5_wm-pyqyp</recordid><startdate>201702</startdate><enddate>201702</enddate><creator>Berlec, Aleš</creator><creator>Perše, Martina</creator><creator>Ravnikar, Matjaž</creator><creator>Lunder, Mojca</creator><creator>Erman, Andreja</creator><creator>Cerar, Anton</creator><creator>Štrukelj, Borut</creator><general>Elsevier B.V</general><general>Elsevier BV</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>201702</creationdate><title>Dextran sulphate sodium colitis in C57BL/6J mice is alleviated by Lactococcus lactis and worsened by the neutralization of Tumor necrosis Factor α</title><author>Berlec, Aleš ; Perše, Martina ; Ravnikar, Matjaž ; Lunder, Mojca ; Erman, Andreja ; Cerar, Anton ; Štrukelj, Borut</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-adada79d958afe0770f4db15e481698b2118c4d17615def78dcfb452bfd831aa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Antibodies, Neutralizing - chemistry</topic><topic>Antibodies, Neutralizing - therapeutic use</topic><topic>Bacteria</topic><topic>Binding</topic><topic>Colitis</topic><topic>Colitis - chemically induced</topic><topic>Colitis - therapy</topic><topic>Colon</topic><topic>Colon - drug effects</topic><topic>Colon - immunology</topic><topic>Crohn's disease</topic><topic>Dextran</topic><topic>Dextran Sulfate</topic><topic>Digestive system</topic><topic>DSS model</topic><topic>Female</topic><topic>Gastrointestinal tract</topic><topic>Humans</topic><topic>Inflammatory bowel disease</topic><topic>Inflammatory bowel diseases</topic><topic>Infliximab</topic><topic>Infliximab - therapeutic use</topic><topic>Intestinal Mucosa - drug effects</topic><topic>Intestine</topic><topic>Laboratory animals</topic><topic>Lactococcus lactis</topic><topic>Lactococcus lactis - chemistry</topic><topic>Lactococcus lactis - immunology</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Monoclonal antibodies</topic><topic>Neutralization</topic><topic>Oral administration</topic><topic>Signal Transduction - drug effects</topic><topic>Sodium</topic><topic>Sulfates</topic><topic>TNFα neutralization</topic><topic>Tumor Necrosis Factor-alpha - immunology</topic><topic>Tumor necrosis factor-TNF</topic><topic>Tumor necrosis factor-α</topic><topic>Ulcerative colitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Berlec, Aleš</creatorcontrib><creatorcontrib>Perše, Martina</creatorcontrib><creatorcontrib>Ravnikar, Matjaž</creatorcontrib><creatorcontrib>Lunder, Mojca</creatorcontrib><creatorcontrib>Erman, Andreja</creatorcontrib><creatorcontrib>Cerar, Anton</creatorcontrib><creatorcontrib>Štrukelj, Borut</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International immunopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Berlec, Aleš</au><au>Perše, Martina</au><au>Ravnikar, Matjaž</au><au>Lunder, Mojca</au><au>Erman, Andreja</au><au>Cerar, Anton</au><au>Štrukelj, Borut</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dextran sulphate sodium colitis in C57BL/6J mice is alleviated by Lactococcus lactis and worsened by the neutralization of Tumor necrosis Factor α</atitle><jtitle>International immunopharmacology</jtitle><addtitle>Int Immunopharmacol</addtitle><date>2017-02</date><risdate>2017</risdate><volume>43</volume><spage>219</spage><epage>226</epage><pages>219-226</pages><issn>1567-5769</issn><eissn>1878-1705</eissn><abstract>TNFα has a well-established role in inflammatory bowel disease that affects the gastrointestinal tract and is usually manifested as Crohn's disease or ulcerative colitis. We have compared Lactococcus lactis NZ9000 displaying TNFα-binding affibody with control Lactococcus lactis and with anti-TNFα antibody infliximab for the treatment of mice with dextran sulphate sodium (DSS)-induced colitis. L. lactis NZ9000 alleviated the colitis severity one week after colitis induction with DSS, more effectively when administered in preventive fashion prior to, during and after DSS administration. TNFα-binding L. lactis was less effective than control L. lactis, particularly when TNFα-binding L. lactis was administered in preventive fashion. Similarly, an apparently detrimental effect of TNFα neutralization was observed in mice that were intraperitoneally administered anti-TNFα monoclonal antibody infliximab prior to colitis induction. The highest concentrations of tissue TNFα were observed in groups without DSS colitis that were treated either with TNFα-binding L. lactis or infliximab. To conclude, we have confirmed that L. lactis exerts a protective effect on DSS-induced colitis in mice. Contrary to expectations, but in line with some reports, the neutralization of TNFα aggravated disease symptoms in the acute phase of colitis and increased TNFα concentration in colon tissue of healthy mice. Nevertheless, we have demonstrated that oral administration of bacteria with surface displayed TNFα-binding affibody can interfere significantly with TNFα signaling and mimic the infliximab response in the given animal model of colitis. [Display omitted] •TNFα-binding and control L. lactis were compared with anti-TNFα antibody in colitis.•L. lactis alleviated the DSS colitis, particularly in preventive administration.•Detrimental effect of TNFα neutralization was observed.•TNFα neutralization without DSS induction highly increased tissue TNFα.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>28039805</pmid><doi>10.1016/j.intimp.2016.12.027</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1567-5769
ispartof International immunopharmacology, 2017-02, Vol.43, p.219-226
issn 1567-5769
1878-1705
language eng
recordid cdi_proquest_miscellaneous_1854801551
source MEDLINE; Elsevier ScienceDirect Journals
subjects Animals
Anti-Inflammatory Agents - therapeutic use
Antibodies, Neutralizing - chemistry
Antibodies, Neutralizing - therapeutic use
Bacteria
Binding
Colitis
Colitis - chemically induced
Colitis - therapy
Colon
Colon - drug effects
Colon - immunology
Crohn's disease
Dextran
Dextran Sulfate
Digestive system
DSS model
Female
Gastrointestinal tract
Humans
Inflammatory bowel disease
Inflammatory bowel diseases
Infliximab
Infliximab - therapeutic use
Intestinal Mucosa - drug effects
Intestine
Laboratory animals
Lactococcus lactis
Lactococcus lactis - chemistry
Lactococcus lactis - immunology
Mice
Mice, Inbred C57BL
Monoclonal antibodies
Neutralization
Oral administration
Signal Transduction - drug effects
Sodium
Sulfates
TNFα neutralization
Tumor Necrosis Factor-alpha - immunology
Tumor necrosis factor-TNF
Tumor necrosis factor-α
Ulcerative colitis
title Dextran sulphate sodium colitis in C57BL/6J mice is alleviated by Lactococcus lactis and worsened by the neutralization of Tumor necrosis Factor α
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T02%3A51%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dextran%20sulphate%20sodium%20colitis%20in%20C57BL/6J%20mice%20is%20alleviated%20by%20Lactococcus%20lactis%20and%20worsened%20by%20the%20neutralization%20of%20Tumor%20necrosis%20Factor%20%CE%B1&rft.jtitle=International%20immunopharmacology&rft.au=Berlec,%20Ale%C5%A1&rft.date=2017-02&rft.volume=43&rft.spage=219&rft.epage=226&rft.pages=219-226&rft.issn=1567-5769&rft.eissn=1878-1705&rft_id=info:doi/10.1016/j.intimp.2016.12.027&rft_dat=%3Cproquest_cross%3E1931697074%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1931697074&rft_id=info:pmid/28039805&rft_els_id=S156757691630529X&rfr_iscdi=true